Erratum to ‘Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration-resistant prostate cancer: The CATS international database’ [European Journal of Cancer, Volume 125 (January 2020) Pages 153–163] (European Journal of Cancer (2020) 125 (153–163), (S0959804919308020), (10.1016/j.ejca.2019.10.030))

Autor: Delanoy, N. Hardy-Bessard, A.-C. Efstathiou, E. Moulec, S.L. Basso, U. Birtle, A. Thomson, A. Krainer, M. Guillot, A. Giorgi, U.D. Hasbini, A. Daugaard, G. Bahl, A. Chowdhury, S. Caffo, O. Beuzeboc, P. Spaeth, D. Eymard, J.-C. Fléchon, A. Alexandre, J. Helissey, C. Butt, M. Priou, F. Lechevallier, E. Deville, J.-L. Gross-Goupil, M. Morales, R. Thiery-Vuillemin, A. Gavrikova, T. Barthélémy, P. Sella, A. Fizazi, K. Ferrero, J.-M. Laguerre, B. Thibault, C. Hans, S. Oudard, S.

The publisher regrets that the following corrections were missed during the publication of this article. Figure 2 legend is missing from the published article and should appear as follows: Figure 2: Overall survival from initiation of each life-exten

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::725099d38d56ceae221156181fccaa47
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3078944

Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial

Autor: M B Manning, D A Streja, C Keller, C H Chung, P L Beckett, A Özdemir, Y M Cho, I Colin, L J Aronne, Erik Christiansen, Markus Laimer, L Van Gaal, S N Lederman, T M O'Connor, L J Klaff, S Aronoff, S H Baik, A V Murray, Signe O R Wallenstein, N A Godbole, H O Høivik, Dilek Gogas Yavuz, A Golay, G T'Sjoen, B Delgado, I N El Ebrashy, E S Kang, C Wium, Bruce W. Bode, Ramazan Sari, B A Palchick, J Geohas, P R Nicol, M Winnie, N Aladağ, E W Braun, C Vercammen, S A Shelbaya, K Sivalingam, S Gorban de Lapertosa, E Riffer, F G Eliaschewitz, J B Buse, B Schultes, C H Sorli, K-W Lee, Mark Warren, T Pieber, S Stäuble, R Prager, A Mertens, A A Arif, D C Eagerton, A Scheen, I J Kim, J A Seo, S Ong, E Ataoglu, John B. Buse, D Berker, A White, F Helland, J C LaRocque, Young Min Cho, Christin L. Hertz, E M Palace, L H S Canani, M P Finneran, S H A Khalil, H L Gulseth, D Weiss, J Condit, E Fließer-Görzer, L Rista, S Akın, M H M F El Hefnawy, N H Kim, C Issa, S Bilz, H Bays, S Fischli, V Preumont, J Pereles-Ortiz, B Bode, E J Morawski, Aytekin Oguz, J Cooper, Tamer Tetiker, Ann Mertens, G Rudofsky, Thomas R. Pieber, W R Litchfield, J L Gross, D L Weinstein

Publikováno v: The lancet. Diabetesendocrinology. 7(7)

BACKGROUND: Oral semaglutide is the first oral formulation of a glucagon-like peptide-1 (GLP-1) receptor agonist developed for the treatment of type 2 diabetes. We aimed to compare the efficacy and safety of flexible dose adjustments of oral semaglut

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e132376f3cbf48c52376523aef27e59f
https://pubmed.ncbi.nlm.nih.gov/31320282

Efficacy and safety of insulin degludec given as part of basal–bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26‐week randomized, open‐label, treat‐to‐target non‐inferiority trial

Autor: Y. Ono, M. A. Gall, G. Bantwal, J. L. Gross, Melanie J. Davies, H. Seino, M. Niemeyer, T. Sasaki

Publikováno v: Diabetes, Obesity & Metabolism

Aims The efficacy and safety of insulin degludec (IDeg) was compared with insulin detemir (IDet), both administered once daily (OD) as basal treatment in participants with type 1 diabetes mellitus (T1DM). The primary outcome was non-inferiority of ID

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a3a3e195bfc7640c6e0c83978271811
https://doi.org/10.1111/dom.12298

Discovery of zinc, selenium, bromine, and neodymium isotopes

Autor: J. Claes, J. L. Gross, Michael Thoennessen, J. Kathawa

Publikováno v: Atomic Data and Nuclear Data Tables. 98:75-94

Currently, thirty-two zinc, thirty-two selenium, twenty-nine bromine and thirty-one neodymium isotopes have been observed and the discovery of these isotopes is discussed here. For each isotope a brief synopsis of the first refereed publication, incl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::523155c96fc4daf83d29edb80ab35547
https://doi.org/10.1016/j.adt.2011.12.001

HbA1cmeasurement for the diagnosis of diabetes: is it enough?

Autor: J. Comerlato, Paula Breitenbach Renz, Gabriela Cavagnolli, J. L. Gross, Joiza Lins Camargo, Carolina Baldisserotto Comerlato

Publikováno v: Diabetic Medicine. 28:31-35

Diabet. Med. 28, 31–35 (2011) Abstract Aim To analyse the performance of HbA1c in diagnosing Type 2 diabetes based on fasting plasma glucose and/or 2-h plasma glucose measurements after a 75-g oral glucose tolerance test. Methods This is a study of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b7506489a978054c392f7127aa7d79b1
https://doi.org/10.1111/j.1464-5491.2010.03159.x